Abstract Background: HER2 (human epidermal growth factor receptor 2) overexpression is a pivotal biomarker for breast cancer prognosis and targeted therapy selection. Conventional assessment requires immunohistochemistry (IHC) and/or in situ hybridization (ISH), which are costly, time-consuming, and constrained by limited tissue and resource availability. In contrast, hematoxylin-and-eosin (H Part 1 (Regular Abstracts); 2026 Apr 17-22; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2026;86(7 Suppl):Abstract nr 5470.
Building similarity graph...
Analyzing shared references across papers
Loading...
Su et al. (Fri,) studied this question.
www.synapsesocial.com/papers/69d1fc8ea79560c99a0a2375 — DOI: https://doi.org/10.1158/1538-7445.am2026-5470
Ziyu Su
Abdul Akbar
Usama Sajjad
Cancer Research
The Ohio State University
The Ohio State University Wexner Medical Center
Building similarity graph...
Analyzing shared references across papers
Loading...